Anzeige
Erschienen in:
07.11.2018 | Leitlinien, Stellungnahmen und Empfehlungen
Statement of the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration
Dated Ocotber 2017
Erschienen in: Die Ophthalmologie | Sonderheft 1/2019
Einloggen, um Zugang zu erhaltenExcerpt
1.
Choroidal neovascularizations (CNV) occur not only in age-related macular degeneration (AMD), but also in numerous other macular and retinal disorders of varying etiology and, if left untreated, can cause irreversible visual loss.
2.
The diagnosis of CNV as well as the indication for treatment should be made in the same way as in neovascular AMD:
-
On initial diagnosis: best-corrected visual acuity, fundus examination, optical coherence tomography (OCT), and fluorescein angiography
-
At follow-up: best-correct visual acuity, fundus examination, OCT, and, depending on findings, fluorescein angiography
3.
Active CNV should be treated with intravitreal operative medication (IVOM) using vascular endothelial growth factor (VEGF) inhibitors if patients have visual acuity of at least 0.05 or if there is sufficient reason to assume that visual acuity could increase to over 0.05 under treatment.
4.
Underlying disorders can include, e. g., (only a selection is presented here):
-
High myopia
-
Angioid streaks
-
Central serous chorioretinopathy
-
Active and inactive uveitis of varying etiology, including retinochoroiditis, chorioretinitis, and choroiditis
-
Eye injuries
-
Retinal dystrophies, e. g., best disease and pattern dystrophies
-
Idiopathic CNV
-
Subretinal masses (osteomas, hamartomas, nevi)